Genmab A/S
DKDKKGenmab A/S (LSE:0MGB) — Biotechnology. Количество бирж, на которых торгуются акции компании: 3. На этой странице — цена и график, дивиденды, крупнейшие держатели и история количества акций.
О компании
- Сайт
- genmab.com
- Сектор
- Healthcare · Biotechnology
- Штаб-квартира
- Copenhagen, Denmark
- Генеральный директор
- Dr. Jan G.J. van de Winkel Ph.D.
- Сотрудники
- 3 119
- На бирже с
- 05.11.2007 (LSE:0MGB)
- Акций в обращении
- 61.49 млн
- Свободное обращение
- 58.96 млн
- Рыночная капитализация
- 152.62 млрд DKK
- Инсайдеры
- 1.12%
- Институциональные инвесторы
- 47.36%
- Отрасль (SIC)
- Pharmaceutical Preparations
- Коэффициент выплат
- 0%
- FCF
- 1.15 млрд USD
- Долг
- 5.27 млрд USD3.1 г. FCF
- Стаж дивидендов
- —
- Прибыль, FCF и выплаченные дивиденды — за 12 месяцев до 31.12.2025 (последний отчёт компании).
Описание
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Дивиденды
Выплаты дивидендов не обнаружены (проверено 10.10.2026). Компания, вероятно, не выплачивает дивиденды.
Новости этой недели
Новостей с сайта компании пока нет.
Крупнейшие держатели
| Держатель | Доля | Акции | Дата отчета |
|---|---|---|---|
| Paradigm Biocapital Advi… | 2.1% | 13.13 млн | 2026-06-30 |
| VANGUARD SPECIALIZED FUN… | 2.05% | 1.28 млн | 2026-07-31 |
| Orbis Allan Gray Ltd | 1.82% | 11.37 млн | 2026-06-30 |
| VANGUARD STAR FUNDS-Vang… | 1.41% | 882 718 | 2026-07-31 |
| Alliancebernstein L.P. | 1.39% | 8.64 млн | 2026-06-30 |
| Deerfield Management Com… | 1.1% | 6.87 млн | 2026-06-30 |
| VANGUARD WORLD FUND-Vang… | 1.05% | 653 206 | 2026-05-31 |
| VANGUARD TAX-MANAGED FUN… | 0.93% | 582 477 | 2026-06-30 |
| Deep Track Capital, Lp | 0.91% | 5.65 млн | 2026-06-30 |
| Arrowstreet Capital, Lim… | 0.8% | 4.98 млн | 2026-06-30 |
| Blackrock Inc. | 0.75% | 4.67 млн | 2026-06-30 |
| HARDING LOEVNER Fd.S INC… | 0.75% | 466 817 | 2026-07-31 |
| Bernstein Fund Inc-Inter… | 0.73% | 458 160 | 2026-06-30 |
| iShares Trust-iShares Co… | 0.72% | 452 332 | 2026-08-31 |
| Sofinnova Investments, I… | 0.65% | 4.05 млн | 2026-06-30 |
| iShares Trust-iShares Bi… | 0.63% | 3.91 млн | 2026-08-31 |
| Renaissance Technologies… | 0.56% | 3.52 млн | 2026-06-30 |
| Two Sigma Investments, L… | 0.56% | 3.51 млн | 2026-06-30 |
| First TRT Exch-Trd Fd.-F… | 0.5% | 3.12 млн | 2026-08-31 |
| Artisan Partners Funds I… | 0.44% | 276 490 | 2026-06-30 |
| Fidelity Concord Street… | 0.38% | 237 328 | 2026-07-31 |
| iShares Trust-iShares MS… | 0.34% | 210 590 | 2026-08-31 |
| American Century ETF Tru… | 0.09% | 546 778 | 2026-08-31 |
| Federated Hermes Equity… | 0.08% | 520 700 | 2026-07-31 |
| Federated Hermes Equity… | 0.06% | 350 000 | 2026-07-31 |
| Federated Hermes World I… | 0.06% | 343 771 | 2026-06-30 |
| RUSSELL INVESTMENT CO-Ta… | 0.05% | 342 344 | 2026-07-31 |
| Mercer Funds-Mercer Non-… | 0.03% | 179 676 | 2026-06-30 |
| SUNAMERICA SERIES TRUST-… | 0.03% | 161 398 | 2026-07-31 |
| Tema ETF Trust-Tema Onco… | 0.03% | 158 861 | 2026-05-31 |
| Pacer Advisors, Inc. | 0% | 58 | 2026-06-30 |
